Immune Design (NASDAQ:IMDZ) issued its quarterly earnings data on Tuesday. The biotechnology company reported ($0.29) EPS for the quarter, topping the consensus estimate of ($0.32) by $0.03, Fidelity Earnings reports. Immune Design had a negative net margin of 2,324.21% and a negative return on equity of 46.95%. The firm had revenue of $0.46 million for the quarter, compared to analyst estimates of $0.75 million.
Immune Design stock traded up $0.03 during mid-day trading on Wednesday, reaching $1.52. 963,326 shares of the company’s stock were exchanged, compared to its average volume of 390,888. The firm has a market cap of $75.62 million, a PE ratio of -0.87 and a beta of 2.54. Immune Design has a twelve month low of $1.29 and a twelve month high of $5.05.
Several equities analysts have recently commented on the stock. HC Wainwright set a $8.00 price objective on shares of Immune Design and gave the stock a “buy” rating in a report on Wednesday. Zacks Investment Research upgraded shares of Immune Design from a “hold” rating to a “buy” rating and set a $2.00 price objective on the stock in a report on Tuesday, October 16th. Royal Bank of Canada restated an “outperform” rating and issued a $11.00 price objective on shares of Immune Design in a report on Friday, October 12th. Finally, Leerink Swann lowered shares of Immune Design from an “outperform” rating to a “market perform” rating in a report on Friday, October 12th. Two investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company. The company has an average rating of “Buy” and an average target price of $7.25.
COPYRIGHT VIOLATION NOTICE: “Immune Design (IMDZ) Posts Quarterly Earnings Results, Beats Estimates By $0.03 EPS” was reported by Week Herald and is the sole property of of Week Herald. If you are accessing this piece of content on another website, it was copied illegally and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this piece of content can be accessed at https://weekherald.com/2018/11/07/immune-design-imdz-posts-quarterly-earnings-results-beats-estimates-by-0-03-eps.html.
Immune Design Company Profile
Immune Design Corp., a clinical-stage immunotherapy company, engages in the research and development of in vivo treatments for cancer. The company primarily develops oncology product candidates based on its ZVex and GLAAS discovery platforms. Its lead products include CMB305, a cancer vaccine targeting the NY-ESO-1 tumor antigen, which is in Phase 2 trial for the treatment of patients with synovial and MRCL sarcoma as a monotherapy; and G100, an antigen agnostic intratumoral product candidate as a monotherapy and combination therapy for the treatment of patients with follicular non-Hodgkin Lymphoma.
Receive News & Ratings for Immune Design Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immune Design and related companies with MarketBeat.com's FREE daily email newsletter.